REFERENCES
- Daniel DG, Wozniak P, Mack RJ, et al (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 34: 61– 9.
- Tamminga CA, Mack RJ, Granneman GR, et al (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12(Suppl 1): S29–35.
- Zimbroff DL, Kane JM, Tamminga CA, et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–91.
- Wong ICK (1999) Pharmacovigilance resources in the United Kingdom. Pharm J 263: 285–8.
- Eckardt L, Haverkamp W, Mertens H, et al (1998) Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol and erythromycin. J Cardiovasc Pharmacol 32: 425–34.
- Eckardt L,Breithardt G, HaverkampW (2002) Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmac ol Exp Ther 300: 64–71.
- Hondeghem LM, Carlsson L, Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004–13.
- Haverkamp W, Eckardt L, Matz J, Frederiksen K (2002) Sertindole: cardiac electrophysiology profile. Int J Psych Clin Prac 6 (Suppl 1): S11–S20.
- Sturkenboom MCJM, Picelli G, Moore N (2001) Mortality during use of sertindole and other anti-psychotics in The Netherlands and Belgium. Pharmacoepidemiol Drug Safety 10: S1–164.
- Eaton WW (1985) Epidemiology of schizophrenia. Epidemiol Rev 7: 105–26.
- Carpenter WT, Buchanan RW (1994) Schizophrenia. N Engl J Med 330: 681–90.